Icotrokinra clinical trial results for psoriasis

Overview

Johnson & Johnson has released long-term Phase 3 clinical trial data for icotrokinra (Icotyde), an oral peptide designed to treat moderate-to-severe plaque psoriasis by blocking the interleukin (IL)-23 receptor.

Data from the ICONIC-TOTAL trial, presented at the 2026 EADV Congress, highlighted sustained clearance in high-impact areas. At week 112, site-specific clearance rates reached 60% for the scalp, 89% for genitals, and 63% for hands and feet.

Complementary results from the ICONIC-LEAD trial involving 684 participants showed that at least 72% maintained a PASI 90 response from week 64 through week 112. Additionally, 44% of patients achieved PASI 100, indicating complete skin clearance, while 78% reported sustained improvement in itch. The study also noted that 85% of patients who previously withdrew from the medication regained a PASI 90 response within 24 weeks of restarting treatment. Throughout both studies, no new safety signals were identified.

Entities

Johnson & Johnson · European Academy of Dermatology and Venereology · Icotyde · Icahn School of Medicine at Mount Sinai · University of Manchester

Timeline

1 day ago

[HEALTH] 4 sources
Johnson & Johnson reports long-term efficacy for oral psoriasis drug Icotyde
Johnson & Johnson’s Phase 3 ICONIC-LEAD trial shows icotrokinra (Icotyde) maintains at least 72% PASI 90 skin clearance through week 112 for moderate-to-severe plaque psoriasis patients.
8 days ago

[HEALTH] 2 sources
Icotrokinra shows sustained psoriasis clearance in 2-year trial
Phase 3 trial data presented at EADV 2026 shows once-daily oral icotrokinra sustains psoriasis clearance in high-impact areas like the scalp and genitals through 112 weeks of treatment.

Sources

consultantlive.com · contemporarypediatrics.com · dermatologytimes.com · mdmag.com · mugglehead.com